Syndax Pharmaceuticals (NASDAQ:SNDX) Issues Earnings Results

Syndax Pharmaceuticals (NASDAQ:SNDX) announced its earnings results on Monday. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.05), FiscalAI reports. Syndax Pharmaceuticals had a negative return on equity of 517.88% and a negative net margin of 72.32%. The company had revenue of $83.30 million for the quarter, compared to analyst estimates of $81.38 million. During the same quarter in the previous year, the company posted ($0.70) earnings per share. Syndax Pharmaceuticals’s revenue for the quarter was up 81.9% on a year-over-year basis.

Here are the key takeaways from Syndax Pharmaceuticals’ conference call:

• Revuforj revenue reached $60.7 million, up 90% year over year and 11% sequentially, with new patient starts rising 20% and prescriptions increasing 13%. Syndax said it maintains dominant share across menin-inhibitor starts and has expanded to more than 620 prescribing accounts.
• Revuforj’s use in NPM1 and KMT2A acute leukemia is increasingly bridging patients to stem-cell transplant, with roughly 40% of NPM1 patients and 50% of KMT2A patients proceeding to transplant. About 50% of NPM1 and 60% of KMT2A patients have resumed therapy afterward, which management expects to become a larger growth driver in 2027 as post-transplant treatment accumulates.
• Niktimvo net revenue increased 47% year over year to $67 million, generating $22.6 million of collaboration revenue for Syndax and lifting its expected margin contribution to the low- to mid-30% range. The company is also advancing frontline chronic GVHD combination trials that could substantially expand the product’s market opportunity.
• Syndax expects multiple clinical catalysts, including expanded frontline Revuforj combination data and real-world evidence at ASH, NUP98 leukemia data in the fourth quarter, and axatilimab frontline results in the first quarter of 2027. Its EGFR inhibitor and next-generation menin inhibitor remain on track to enter clinical development next year.
• The company ended the quarter with $551 million in cash and reiterated approximately $400 million of 2026 R&D and SG&A expenses, saying it is funded through its current priorities. CFO Keith Goldan will retire, with Aaron Ondrey scheduled to succeed him on November 9, 2026; management did not provide updated timing for frontline Revuforj enrollment completion or approval.

Syndax Pharmaceuticals Price Performance

Shares of SNDX stock opened at $14.29 on Wednesday. Syndax Pharmaceuticals has a 52-week low of $12.80 and a 52-week high of $25.59. The stock has a market cap of $1.27 billion, a PE ratio of -6.06 and a beta of 0.48. The company has a debt-to-equity ratio of 38.95, a quick ratio of 6.44 and a current ratio of 6.77. The firm’s 50 day moving average price is $16.95 and its two-hundred day moving average price is $20.18.

Trending Headlines about Syndax Pharmaceuticals

Here are the key news stories impacting Syndax Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue rose 82% year over year to $83.3 million, topping estimates. Revuforj revenue increased 90% to $60.7 million, with new patients up 20% quarter over quarter; Niktimvo sales grew 47% to $67.4 million, generating $22.6 million in collaboration revenue for Syndax. These results support the company’s growing commercial business. Syndax Q3 2026 results and business update
• Positive Sentiment: Syndax expects additional revumenib data in the fourth quarter from trials and real-world studies, offering potential upcoming pipeline catalysts. Syndax Q3 2026 results and business update
• Neutral Sentiment: Aaron A. Ondrey was appointed CFO effective November 9. Current CFO Keith A. Goldan plans to retire and will remain through year-end to help with the transition; no reason for the change was given. Syndax CFO transition announcement
• Negative Sentiment: The company reported a third-quarter loss of $0.55 per share, missing the roughly $0.50 consensus estimate. Coverage also flagged pipeline setbacks as a concern that could temper the positive commercial trends. Syndax Q3 earnings and pipeline coverage
• Negative Sentiment: Pomerantz LLP said it is investigating potential claims on behalf of Syndax investors. The announcement provides no findings, but the investigation may create an additional overhang. Pomerantz investor investigation announcement

Insider Buying and Selling

In other Syndax Pharmaceuticals news, Director Dennis Podlesak sold 8,000 shares of the company’s stock in a transaction on Thursday, October 29th. The shares were sold at an average price of $14.21, for a total transaction of $113,680.00. Following the completion of the sale, the director owned 239,763 shares in the company, valued at approximately $3,407,032.23. The trade was a 3.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.80% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on SNDX. HC Wainwright dropped their price objective on shares of Syndax Pharmaceuticals from $38.00 to $36.00 and set a “buy” rating for the company in a research report on Tuesday. Jefferies Financial Group reaffirmed a “buy” rating and set a $35.00 price objective on shares of Syndax Pharmaceuticals in a report on Tuesday, September 29th. Weiss Ratings upgraded Syndax Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday. UBS Group reissued a “buy” rating on shares of Syndax Pharmaceuticals in a research note on Thursday, October 1st. Finally, JPMorgan Chase & Co. lowered their target price on Syndax Pharmaceuticals from $44.00 to $40.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $41.60.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc (NASDAQ:SNDX) is a biopharmaceutical company focused on developing and commercializing therapies for cancer and immune-related diseases. Founded in 2005 and headquartered in Waltham, Massachusetts, the company develops medicines designed to address genetically defined cancers and serious complications associated with cancer treatment.

Syndax’s lead product is Revuforj (revumenib), an oral menin inhibitor approved in the United States for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in eligible adults and children.